Singapore Institute of Advanced Medicine Holdings Ltd. (SG:9G2)
SGX:9G2
Want to see SG:9G2 full AI Analyst Report?
Top Page
Singapore Institute of Advanced Medicine Holdings Ltd.
(SGX:9G2)
Select Model
Select Model
Rating:43Neutral
Price Target:
S$0.03
▼(-54.29% Downside)
Action:Reiterated
Date:05/28/26
The score is held down primarily by very weak profitability and continued cash burn alongside rising leverage risk. Technical indicators are broadly bearish despite oversold readings, and valuation is constrained by a negative P/E that reflects ongoing losses.
Positive Factors
Revenue growth
A near-doubling of revenue in 2025 indicates meaningful demand expansion or successful commercialization of services. Sustained revenue scale improves operating leverage potential and provides a base to absorb fixed costs if management controls SG&A, supporting medium-term viability.
Negative Factors
Deep operating losses
Persistently large operating and net losses mean core costs and overhead far exceed gross profit despite revenue gains. Without decisive cuts or revenue continuing to scale faster than SG&A, losses will erode equity and hinder ability to reach sustainable profitability over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth
A near-doubling of revenue in 2025 indicates meaningful demand expansion or successful commercialization of services. Sustained revenue scale improves operating leverage potential and provides a base to absorb fixed costs if management controls SG&A, supporting medium-term viability.
Read all positive factors
Singapore Institute of Advanced Medicine Holdings Ltd. (9G2) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$56.90M
Dividend YieldN/A
Average Volume (3M)247.96K
Price to Earnings (P/E)―
Beta (1Y)-0.23
Revenue Growth-1.27%
EPS Growth16.67%
CountrySG
Employees107
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,724,092,500
10 Day Avg. Volume138,640
30 Day Avg. Volume247,960
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.55
Price to Sales (P/S)1.94
P/FCF Ratio-2.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Singapore Institute of Advanced Medicine Holdings Ltd. Business Overview & Revenue Model
Company Description
Singapore Institute of Advanced Medicine Holdings Ltd. operates as a holding company primarily focused on delivering healthcare services. Its operations include providing pharmaceutical products, surgical supplies, and medical laboratory services....
How the Company Makes Money
null...
Singapore Institute of Advanced Medicine Holdings Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2024 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.74M | 15.71M | 16.65M | 16.23M | 13.81M | 12.92M |
| Gross Profit | -8.36M | 14.42M | 15.36M | -2.60M | -4.31M | -2.32M |
| EBITDA | -12.58M | -11.08M | -13.42M | -10.60M | -8.02M | -3.06M |
| Net Income | -30.81M | -26.16M | -37.45M | -18.07M | -12.43M | -9.35M |
Balance Sheet | ||||||
| Total Assets | 122.30M | 124.71M | 138.76M | 159.52M | 174.36M | 172.08M |
| Cash, Cash Equivalents and Short-Term Investments | 2.48M | 2.84M | 3.16M | 11.05M | 15.84M | 10.29M |
| Total Debt | 58.62M | 58.21M | 46.10M | 80.77M | 87.30M | 92.26M |
| Total Liabilities | 78.02M | 69.07M | 57.01M | 114.60M | 120.31M | 112.90M |
| Stockholders Equity | 44.28M | 55.64M | 81.74M | 44.93M | 54.05M | 59.18M |
Cash Flow | ||||||
| Free Cash Flow | -5.61M | -10.78M | -14.80M | -19.89M | -11.26M | -9.72M |
| Operating Cash Flow | -5.00M | -10.63M | -14.26M | -5.45M | -7.15M | -4.26M |
| Investing Cash Flow | -166.41K | 113.13K | -263.72K | -1.45M | 3.72M | -5.25M |
| Financing Cash Flow | 2.29M | 10.20M | 6.64M | 2.11M | 9.18M | 10.66M |
Singapore Institute of Advanced Medicine Holdings Ltd. Technical Analysis
Negative
0.07
Price Trends
0.04
Negative
0.04
Negative
0.04
Negative
Market Momentum
>-0.01
Positive
41.03
Neutral
-33.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:9G2, the sentiment is Negative. The current price of 0.07 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.03 is Neutral, neither overbought nor oversold. The STOCH value of -33.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:9G2.
Singapore Institute of Advanced Medicine Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | S$58.45M | 11.55 | 34.20% | 3.37% | -0.99% | 140.00% | |
68 Neutral | S$1.78B | 36.61 | 4.62% | 2.45% | 1.83% | 14.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | S$1.45B | -35.40 | -8.49% | ― | 6.95% | ― | |
43 Neutral | S$56.90M | -0.94 | -79.37% | ― | -1.27% | 16.67% |
* Healthcare Sector Average
SG:9G2
Singapore Institute of Advanced Medicine Holdings Ltd.
0.03
<0.01
22.22%
SG:BSL
Raffles Medical Group
0.95
<0.01
0.53%
SG:A50
Thomson Medical Group Ltd.
0.06
0.01
30.95%
SG:1B1
HC Surgical Specialists Ltd
0.38
0.10
34.75%
SG:40T
ISEC Healthcare Ltd
0.32
-0.03
-8.05%
SG:5WA
OUE Lippo Healthcare Limited
0.04
0.02
82.61%
Singapore Institute of Advanced Medicine Holdings Ltd. Corporate Events
Advanced Medicine Holdings Starts Rights-cum-Warrants Issue and Sends Offer Documents to Investors
Jun 4, 2026
Singapore Institute of Advanced Medicine Holdings has launched a renounceable, non-underwritten rights-cum-warrants issue and has begun sending notification letters and application forms to entitled shareholders. The documents provide instructions...
Singapore Institute of Advanced Medicine Wins SGX Nod for Major Rights and Warrants Issue
May 12, 2026
Singapore Institute of Advanced Medicine Holdings has received approval in principle from the Singapore Exchange for a renounceable non-underwritten rights cum warrants issue on the Catalist board. The offer will comprise up to 492.6 million new s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.